New Study Identifies Effective Treatments for Melanoma-Associated Leptomeningeal Disease
Source: Targeted Oncology, December 2024
In an interview, Vincent Law, of Moffitt Cancer Center, discussed a new study that offers hope for patients with melanoma brain metastasis.
One obstacle in developing effective treatments for patients with leptomeningeal disease has been the lack of reliable models to study the disease. However, a recent study has addressed this challenge by establishing methods to culture melanoma cells derived from patient spinal fluid samples in both laboratory and preclinical models.
Researchers at the Moffitt Cancer Center were able to utilize these models and screen existing drugs, allowing them to identify several promising candidates. Some of these included ponatinib (Iclusig), sorafenib (Nexavar), ceritinib (Zykadia), and homoharringtonine (HHT).